期刊
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
卷 13, 期 1, 页码 59-71出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425255.2017.1230200
关键词
Colistin; XDR; Klebsiella pneumoniae; Pseudomonas aeruginosa; Acinetobacter baumannii; combinations; clinical efficacy; PK; PD; mcr-1 resistance gene; interactions
Introduction: Living in the era of antibiotic resistance' and facing the threat of an end to antibiotics', physicians in the last decade have revived use of colistin, since the available literature at the clinical level was poor and limitedAreas covered: Herein, the authors present the current available knowledge regarding colistin, i.e. in vitro activity and interactions, current pharmacokinetics/pharmacodynamics (PK/PD), clinical efficacy against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria, as well as toxicity issues, whereas the recently published newer plasmid mediated mcr-1 resistance gene is reviewed and discussed.Expert opinion: As proven in a big number of studies and despite their retrospective design, it is surmized that for carbapenemase producing K. pneumoniae, colistin should be given in combination with another active in vitro antibiotic and preferably meropenem/doripenem whenever the relevant minimum inhibitory concentration is 8mg/L. However, colistin monotherapy seems adequate for infections caused by A. baumannii and P. aeruginosa. Based on current knowledge on PK/PD, appropriate dosage schedules are discussed in detail. The worldwide fear of the spread of the plasmid mediated mcr-1 colistin resistance gene is prevailing which, if not limited, the real catastrophy of a life-saver antibiotic will follow soon.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据